|
gptkbp:instanceOf
|
gptkb:drug
antihistamine
|
|
gptkbp:approvedBy
|
1996
|
|
gptkbp:ATCCode
|
gptkb:R06AX26
|
|
gptkbp:bioavailability
|
30%
|
|
gptkbp:brand
|
gptkb:Allegra
|
|
gptkbp:CASNumber
|
153439-40-8
|
|
gptkbp:chemicalFormula
|
C32H39NO4
|
|
gptkbp:contraindication
|
hypersensitivity to fexofenadine
|
|
gptkbp:developedBy
|
gptkb:Sanofi_Aventis
|
|
gptkbp:drugClass
|
second-generation antihistamine
|
|
gptkbp:eliminationHalfLife
|
14 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
fexofenadine
|
|
gptkbp:legalStatus
|
OTC in some countries
Prescription in some countries
|
|
gptkbp:mechanismOfAction
|
selective peripheral H1 receptor antagonist
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:notableFor
|
non-sedating antihistamine
|
|
gptkbp:predecessor
|
terfenadine
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
60% to 70%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
headache
drowsiness
|
|
gptkbp:synonym
|
gptkb:Allegra
Telfast
Fexigra
Fexodane
Fexofenadinum
|
|
gptkbp:usedFor
|
allergic rhinitis
chronic urticaria
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:CYP3A5
gptkb:antihistamine
gptkb:Anofex
|
|
gptkbp:bfsLayer
|
6
|